Preview

Кардиология

Расширенный поиск

Патогенетические механизмы развития патологии миокарда у больных со злокачественными новообразованиями: современное состояние проблемы

https://doi.org/10.18087/cardio.2020.2.n985

Полный текст:

Аннотация

Миокард, обладающий высокой метаболической активностью, реагирует на нарушения обмена веществ и энергетический дисбаланс под действием растущего злокачественного новообразования. Кроме того, сама опухоль способна продуцировать вещества, оказывающие непосредственное влияние на обменные процессы и жизненный цикл не затронутых опухолевым процессом клеток, в том числе кардиомиоцитов. В обзоре резюмированы и систематизированы имеющиеся на сегодняшний день данные исследований, посвященных отдельным аспектам повреждающего действия онкогенов и факторов, связанных с опухолевым процессом, на сердечную мышцу, морфофункциональным изменениям со стороны сердечно-сосудистой системы онкологических пациентов, подробно описаны патогенетические механизмы их развития.

Об авторах

А. Г. Обрезан
ГОУ ВПО «Санкт-Петербургский государственный университет»; Международный медицинский центр «СОГАЗ»
Россия

Санкт-Петербург



Н. В. Щербакова
ГОУ ВПО «Санкт-Петербургский государственный университет»
Россия

Щербакова Наталья Владимировна



Список литературы

1. Burch GE, Phillips JH, Ansari A. The Cachectic Heart. Diseases of the Chest. 1968;54(5):403–9. DOI: 10.1378/chest.54.5.403

2. Houten L, Reilley AA. An investigation of the cause of death from cancer. Journal of Surgical Oncology. 1980;13(2):111–6. DOI: 10.1002/jso.2930130205

3. Mamidanna R, Nachiappan S, Bottle A, Aylin P, Faiz O. Defining the timing and causes of death amongst patients undergoing colorectal resection in England. Colorectal Disease. 2016;18(6):586–93. DOI: 10.1111/codi.13224

4. McBride W, Jackman JD, Grayburn PA. Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma. The American Journal of Medicine. 1990;89(1):21–4. DOI: 10.1016/0002-9343(90)90092-R

5. Drott C, Lundholm K. Glucose uptake and amino acid metabolism in perfused hearts from tumor-bearing rats. Journal of Surgical Research. 1990;49(1):62–8. DOI: 10.1016/0022-4804(90)90112-F

6. Maron BJ. Contemporary Definitions and Classification of the Cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Coun­cil on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16. DOI: 10.1161/CIRCULATIONAHA.106.174287

7. Belenkov Yu.N., Oganov R.G. Cardiology: National guide. – M.: GEOTAR-Media; 2011. – 1232 p. [Russian: Беленков Ю.Н., Оганов Р.Г. Кардиология: национальное руководство. – М.: ГЭОТАР-Медиа, 2011. - 1232с]. ISBN 978-5-9704-2767-5

8. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. The Journal of General Physiology. 1927;8(6):519–30. DOI: 10.1085/jgp.8.6.519

9. Shapot V.S. Biochemical aspects of tumor growth. -M.: Medicine;1975. - 304 p. [Russian: Шапот В.С. Биохимические аспекты опухолевого роста. - М.: Медицина, 1975. - 304c]

10. Anichkov N.M., Kvetnoy I.M., Konovalov S.S. Biology of tumor growth. – SPb.: Prime-Euroznak; M.: Olma-Press;2004. – 216 p. [Russian: Аничков Н.М., Кветной И.М., Коновалов С.С. Биология опухолевого роста. – СПб: Прайм-Еврознак; M.: Олма-Пресс, 2004. – 216c]. ISBN 5-94946-090-1

11. Humberstone DA, Shaw JH. Metabolism in hematologic malignancy. Cancer. 1988;62(8):1619–24. DOI: 10.1002/1097-0142(19881015)62:8<1619::aid-cncr2820620827>3.0.co;2-c

12. Dempsey DT, Feurer ID, Knox LS, Crosby LO, Buzby GP, Mullen JL. Energy expenditure in malnourished gastrointestinal cancer patients. Cancer. 1984;53(6):1265–73. DOI: 10.1002/1097-0142(19840315)53:6<1265::aid-cncr2820530609>3.0.co;2-2

13. Ado A.D. Pathological physiology. – M.: Triada-X;2000. – 573 p. [Russian: Адо А.Д. Патологическая физиология. – М.: Триада-Х, 2000. – 573c. Доступно на: https://studfile.net/preview/1818857/]. ISBN 5-8249-0023-X

14. Homburger F, Young NF. Hypoproteinemia in patients with gastric cancer; its persistence after operation in the presence of body tissue repletion. Blood. 1948;3(12):1460–71. PMID: 18893858

15. Jarnum S, Schwartz M. Hypoalbuminemia in gastric carcinoma. Gastroenterology. 1960; 38: 769–76. PMID: 14406821

16. Casiero D, Frishman WH. Cardiovascular Complications of Eating Disorders. Cardiology in Review. 2006;14(5):227–31. DOI: 10.1097/01.crd.0000216745.96062.7c

17. Cosper PF, Leinwand LA. Cancer Causes Cardiac Atrophy and Autophagy in a Sexually Dimorphic Manner. Cancer Research. 2011;71(5):1710–20. DOI: 10.1158/0008-5472.CAN-10-3145

18. Tian M, Asp ML, Nishijima Y, Belury M. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. International Journal of Oncology. 2011;39(5):1321–6. DOI: 10.3892/ijo.2011.1150

19. Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury. Cardiac alterations in cancer-induced cachexia in mice. International Journal of Oncology. 2010;37(2):347–53. DOI: 10.3892/ijo_00000683

20. Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal. 2014;35(14):932–41. DOI: 10.1093/eurheartj/eht302

21. Xu H, Crawford D, Hutchinson KR, Youtz DJ, Lucchesi PA, Velten M et al. Myocardial dysfunction in an animal mo­del of cancer cachexia. Life Sciences. 2011;88(9–10):406–10. DOI: 10.1016/j.lfs.2010.12.010

22. Sweeney M, Yiu A, Lyon AR, et al. Cardiac Atrophy and Heart Failure in Cancer. Cardiac Failure Review. 2017;3(1):62–6. DOI: 10.15420/cfr.2017:3:2

23. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F et al. Increased Muscle Proteasome Activity Correlates with Disease Severity in Gastric Cancer Patients. Annals of Surgery. 2003;237(3):384–9. DOI: 10.1097/01.SLA.0000055225.96357.71

24. Olbinskaya L.I., Ignatenko S.B. The role of cytokine aggression in the pathogenesis of cardiac cachexia syndrome in patients with chronic heart failure. Russian Heart Failure Journal. 2001;2 (3):132–4. [Russian: Ольбинская Л. И., Игнатенко С. Б. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2001;2(3):132–4]

25. Padrão AI, Moreira-Gonçalves D, Oliveira PA, Teixeira C, Faustino-Rocha AI, Helguero L et al. Endurance training prevents TWEAK but not myostatin-mediated cardiac remodelling in cancer cachexia. Archives of Biochemistry and Biophysics. 2015; 567: 13–21. DOI: 10.1016/j.abb.2014.12.026

26. Neylon CB, Bryant SM, Little PJ, Bobik A. Transforming Growth Factor-β1 Regulates the Expression of Ryanodine-Sensitive Ca2+ Oscillations in Cardiac Myocytes. Biochemical and Biophysical Research Communications. 1994;204(2):678–84. DOI: 10.1006/bbrc.1994.2513

27. Hinch ECA, Sullivan-Gunn MJ, Vaughan VC, McGlynn MA, Lewandowski PA. Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice. Journal of Cache­xia, Sarcopenia and Muscle. 2013;4(4):287–93. DOI: 10.1007/s13539-013-0116-8

28. Egan D, Kim J, Shaw RJ, Guan K-L. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy. 2011;7(6):643–4. DOI: 10.4161/auto.7.6.15123

29. Manne NDPK, Lima M, Enos RT, Wehner P, Carson JA, Blough E. Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse. International Journal of Oncology. 2013;42(6):2134–40. DOI: 10.3892/ijo.2013.1893

30. Dang CV. Links between metabolism and cancer. Genes & Development. 2012;26(9):877–90. DOI: 10.1101/gad.189365.112

31. Murphy KT. The pathogenesis and treatment of cardiac atrophy in cancer cachexia. American Journal of Physiology-Heart and Circulatory Physiology. 2016;310(4):H466–77. DOI: 10.1152/ajpheart.00720.2015

32. Nomura DK, Cravatt BF. Lipid metabolism in cancer. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Li­pids. 2013;1831(10):1497–8. DOI: 10.1016/j.bbalip.2013.08.001

33. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Research. 1953;13(1):27–9. PMID: 13032945

34. Lingwood D, Simons K. Lipid Rafts as a Membrane-Organizing Principle. Science. 2010;327(5961):46–50. DOI: 10.1126/science.1174621

35. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews Drug Discovery. 2007;6(7):541–55. DOI: 10.1038/nrd2221

36. Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS et al. Lipid Bodies Are Reservoirs of Cyclooxygenase-2 and Sites of Prostaglandin-E2 Synthesis in Colon Cancer Cells. Cancer Research. 2008;68(6):1732–40. DOI: 10.1158/0008-5472.CAN-07-1999

37. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer and Prostatic Diseases. 2006;9(3):230–4. DOI: 10.1038/sj.pcan.4500879

38. Khasawneh J, Schulz MD, Walch A, Rozman J, de Angelis MH, Klingenspor M et al. Inflammation and mitochondrial fatty acid -oxidation link obesity to early tumor promotion. Proceedings of the National Academy of Sciences. 2009;106(9):3354–9. DOI: 10.1073/pnas.0802864106

39. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nature Reviews Cancer. 2006;6(3):184–92. DOI: 10.1038/nrc1819

40. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S et al. SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth. Cell Metabolism. 2008;8(3):224–36. DOI: 10.1016/j.cmet.2008.07.007

41. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes & Development. 2000;14(1):34–44. PMID: 10640274

42. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell. 2005;7(1):77–85. DOI: 10.1016/j.ccr.2004.11.022

43. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology. 1996;16(9):4604–13. DOI: 10.1128/MCB.16.9.4604

44. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer. 2008;8(9):705–13. DOI: 10.1038/nrc2468

45. Santos CR, Schulze A. Lipid metabolism in cancer: Lipid meta­bolism in cancer. FEBS Journal. 2012;279(15):2610–23. DOI: 10.1111/j.1742-4658.2012.08644.x

46. Goh J, Endicott E, Ladiges WC. Pre-tumor exercise decreases breast cancer in old mice in a distance-dependent manner. American Journal of Cancer Research. 2014;4(4):378–84. PMID: 25057440

47. Krivchik A.A., Vismont F.I., Zhadan S.A. Typical forms of structu­ral-functional subcellular organelles in case of damage. – Minsk: BSMU;2004. – 52 p. [Russian: Кривчик А.А., Висмонт Ф.И., Жадан С.А. Типовые формы структурно-функциональных субклеточных органелл при повреждении. - Минск: БГМУ, 2004. – 52c]. ISBN 985-462-298-3

48. Fermoselle C, García-Arumí E, Puig-Vilanova E, Andreu AL, Urtreger AJ, de Kier Joffé EDB et al. Mitochondrial dysfunction and thera­peutic approaches in respiratory and limb muscles of cancer cachectic mice: Mitochondrial respiratory chain dysfunction in cachexia. Experimental Physiology. 2013;98(9):1349–65. DOI: 10.1113/expphysiol.2013.072496

49. Marin-Corral J, Fontes CC, Pascual-Guardia S, Sanchez F, Olivan M, Argilés JM et al. Redox Balance and Carbonylated Proteins in Limb and Heart Muscles of Cachectic Rats. Antioxidants & Redox Signaling. 2010;12(3):365–80. DOI: 10.1089/ars.2009.2818

50. Carew JS, Huang P. Mitochondrial defects in cancer. Molecular Cancer. 2002;1(1):9. DOI: 10.1186/1476-4598-1-9

51. Berstein L.M., Prokhorova V.I., Konoplya E.F. Cancer and cyclic nucleotides: tumor growth mechanisms, hormone sensitivity of tumor tissue, clinical oncology problems. -Minsk: Science and Technology;1993. – 230 p. [Russian: Берштейн Л. М., Прохорова В. И., Конопля Е. Ф. Рак и циклические нуклеотиды: механизмы опухолевого роста, гормоночувствительность опухолевой ткани, проблемы клинической онкологии. – Минск: Наука и техника, 1993. – 230c]. ISBN 978-5-343-00838-8

52. Ostrovsky Yu.M. Active centers and groupings in the thiamine molecule. -Minsk: Science and Technology;1975. - 423 p. [Russian: Островский Ю.М. Активные центры и группировки в молекуле тиамина. – Минск: Наука и техника, 1975. – 423 c.]

53. Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S. Proteolytic-antiproteolytic balance and its regulation in carcino­genesis. World Journal of Gastroenterology. 2005;11(9):1251. DOI: 10.3748/wjg.v11.i9.1251

54. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American Journal of Clinical Nutrition. 2006;83(6):1345–50. DOI: 10.1093/ajcn/83.6.1345

55. Makeeva T.K., Galkin A.A. Trofological status of patients with stomach cancer. Bulletin of St. Petersburg State University. Medicine. 2008; S1:105–17. [Russian: Макеева Т. К., Галкин А. А. Трофологический статус больных раком желудка. Вестник Санкт-Петербургского государственного университета. Медицина. 2008;S1:105-17]

56. Esper DH, Harb WA. The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations. Nutrition in Clinical Practice. 2005;20(4):369–76. DOI: 10.1177/0115426505020004369

57. Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W et al. Cardiovascular Function and Predictors of Exer­cise Capacity in Patients with Colorectal Cancer. Journal of the American College of Cardiology. 2014;64(13):1310–9. DOI: 10.1016/j.jacc.2014.07.948

58. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer. 2004;40(15):2293–306. DOI: 10.1016/j.ejca.2004.06.019

59. Acher PL, Al-Mishlab T, Rahman M, Bates T. Iron-deficiency anaemia and delay in the diagnosis of colorectal cancer. Colorectal Disease. 2003;5(2):145–8. DOI: 10.1046/j.1463-1318.2003.00415.x

60. Blyndar V.N., Zubrikhina G.N., Matveyeva I.I. Algorithm of modern laboratory diagnostics of anemic syndrome in oncological patients. Russian Clinical Laboratory Diagnostics. 2012;7:19–24. [Russian: Блиндарь В. Н., Зубрихина Г. Н., Матвеева И. И. Алгоритм современной лабораторной диагностики анемического синдрома у онкологических больных. Клиническая лабораторная диагностика. 2012;7:19-24]

61. Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematology/Oncology Clinics of North America. 1996;10(2):365–76. DOI: 10.1016/S0889-8588(05)70343-9

62. Sheptulin A.A. Bleeding from the lower sections of the gastrointestinal tract. Supplement RMJ “Diseases of the Digestive system”. 2000;2:36–43. [Russian: Шептулин А.А. Кровотечения из нижних отделов желудочно-кишечного тракта. Приложение РМЖ «Болезни Органов Пищеварения». 2000; 2: 36-43]

63. Novik A.V. Anemia and metabolic disorders in cancer patients. Practical Oncology. 2009;10(3):131–40. [Russian: Новик А.В. Анемия и метаболические расстройства у онкологических больных. Практическая онкология. 2009;10(3):131-40]

64. Moiseev S.V. Capacities of somatostatin analogues to treat castration-resistant prostate cancer. P.A. Herzen Journal of Oncology. 2012;1(1):77–82. [Russian: Моисеев С.В. Анемия при онкологических заболеваниях. Онкология. Журнал им. П. А. Герцена. 2012;1(1):77-82]

65. Goncharova E.V., Govorin A.V., Kuzmin A.G., Barkan V.S., Filev A.P. Структурно-функциональные показатели миокарда у больных хронической железодефицитной анемией. Kardiolo­giia. 2008;48 (5):46–50. [Russian: Гончарова Е. В. Говорин А. В., Кузьмин А.Г., Баркан В.С., Филев А.П. Структурно-функ­цио­нальные показатели миокарда у больных хронической железодефицитной анемией. Кардиология. 2008; 48(5): 46-50]

66. Kripak O.N. Features of changes in systemic and intracardiac hemodynamics in patients with myocardial dystrophy of various origin. Bulletin of the Russian Military Medical Academy. 2009;1(25):125–30. [Russian: Крипак О.Н. Особенности изменения системной и внутрисердечной гемодинамики у пациентов с миокардиодистрофиями различного происхождения. Вестник Российской Военно-медицинской академии. 2009;1(25):125-30]

67. Wakui A. Electrolyte abnormalities associated with cancer: a review. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 1986;13(6):2031–8. PMID: 3521493


Для цитирования:


Обрезан А.Г., Щербакова Н.В. Патогенетические механизмы развития патологии миокарда у больных со злокачественными новообразованиями: современное состояние проблемы. Кардиология. 2020;60(2):142-154. https://doi.org/10.18087/cardio.2020.2.n985

For citation:


Obrezan A.G., Shcherbakova N.V. Pathogenetic mechanisms of development of myocardial pathology in patients with malignant tumors: the current state of the problem. Kardiologiia. 2020;60(2):142-154. https://doi.org/10.18087/cardio.2020.2.n985

Просмотров: 210


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)